ClinicalTrialsFinder
RecruitingPhase 2NCT07090161

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Sponsor

Vanda Pharmaceuticals

Enrollment

240 participants

Start Date

Sep 15, 2025

Study Type

INTERVENTIONAL

Conditions

HypertensionUncontrolled Hypertension

Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether iloperidone — a drug currently approved for schizophrenia — can help lower blood pressure in people whose hypertension (high blood pressure) is not well-controlled despite being on other blood pressure medications. **You may be eligible if...** - Your systolic blood pressure (the top number) is 130 mmHg or higher despite being on at least one blood pressure medication for more than 8 weeks **You may NOT be eligible if...** - Your blood pressure is extremely high (systolic ≥ 180 mmHg or diastolic ≥ 120 mmHg — Grade 3 / severe hypertension) - You have unstable heart disease - You have significant kidney problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGiloperidone

iloperidone

DRUGPlacebo

placebo comparator

Locations(28)

Vanda Investigative Site

Phoenix, Arizona, United States

Vanda Investigative Site

Tempe, Arizona, United States

Vanda Investigative Site

Tucson, Arizona, United States

Vanda Investigative Site

Chula Vista, California, United States

Vanda Investigative Site

Dublin, California, United States

Vanda Investigative Site

Valencia, California, United States

Vanda Investigative Site

Walnut Creek, California, United States

Vanda Investigative Site

Doral, Florida, United States

Vanda Investigative Site

Fort Myers, Florida, United States

Vanda Investigative Site

Columbus, Georgia, United States

Vanda Investigative Site

Oak Brook, Illinois, United States

Vanda Investigative Site

Tinley Park, Illinois, United States

Vanda Investigative Site

El Dorado, Kansas, United States

Vanda Investigative Site

Wichita, Kansas, United States

Vanda Investigative Site

Lexington, Kentucky, United States

Vanda Investigative Site

Hazelwood, Missouri, United States

Vanda Investigative Site

Las Vegas, Nevada, United States

Vanda Investigative Site

Mount Kisco, New York, United States

Vanda Investigative Site

Rochester, New York, United States

Vanda Investigative Site

Kinston, North Carolina, United States

Vanda Investigative Site

Cincinnati, Ohio, United States

Vanda Investigative Site

Norman, Oklahoma, United States

Vanda Investigative Site

Oklahoma City, Oklahoma, United States

Vanda Investigative Site

Charleston, South Carolina, United States

Vanda Investigative Site

Carrollton, Texas, United States

Vanda Investigative Site

Salt Lake City, Utah, United States

Vanda Investigative Site

Burke, Virginia, United States

Vanda Investigative Site

Norfolk, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07090161

Related Trials

Diabetes and Heart Disease Risk in Blacks

NCT000018531 location

Genetics of Type 2 Diabetes in West Africans

NCT008371225 locations

Hypertension Explored in Long-term Postpartum Follow-up in Later Life

NCT061870121 location

Hypertension Management in Young Adults Personalised by Echocardiography and Clinical Outcome.

NCT037624991 location

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT070644731152 locations